REFERENCES

1. Wong VW, Ekstedt M, Wong GL, Hagström H. Changing epidemiology, global trends and implications for outcomes of NAFLD. J Hepatol. 2023;79:842-52.

2. Rinella ME, Lazarus JV, Ratziu V, et al; NAFLD Nomenclature consensus group. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Hepatology. 2023;78:1966-86.

3. Hagström H, Shang Y, Hegmar H, Nasr P. Natural history and progression of metabolic dysfunction-associated steatotic liver disease. Lancet Gastroenterol Hepatol. 2024;9:944-56.

4. Jarvis H, Craig D, Barker R, et al. Metabolic risk factors and incident advanced liver disease in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of population-based observational studies. PLoS Med. 2020;17:e1003100.

5. Marti-Aguado D, Calleja JL, Vilar-Gomez E, et al. Low-to-moderate alcohol consumption is associated with increased fibrosis in individuals with metabolic dysfunction-associated steatotic liver disease. J Hepatol. 2024;81:930-40.

6. Jamialahmadi O, De Vincentis A, Tavaglione F, et al. Partitioned polygenic risk scores identify distinct types of metabolic dysfunction-associated steatotic liver disease. Nat Med. 2024;30:3614-23.

7. Marchesini G, Vettor R, Pinzani M. MASLD emerging from the fog of fatty liver. J Hepatol. 2024;80:178-80.

8. Jiang F, Wang L, Ying H, et al. Multisystem health comorbidity networks of metabolic dysfunction-associated steatotic liver disease. Med. 2024;5:1413-23.e3.

9. Stine JG, Long MT, Corey KE, et al. American College of Sports Medicine (ACSM) international multidisciplinary roundtable report on physical activity and nonalcoholic fatty liver disease. Hepatol Commun. 2023;7:e0108.

10. Stine JG, Long MT, Corey KE, et al. Physical activity and nonalcoholic fatty liver disease: a roundtable statement from the american college of sports medicine. Med Sci Sports Exerc. 2023;55:1717-26.

11. Sherry AP, Willis SA, Yates T, et al. Physical activity is inversely associated with hepatic fibro-inflammation: a population-based cohort study using UK Biobank data. JHEP Rep. 2023;5:100622.

12. Rinella ME, Lazarus JV, Ratziu V, et al; NAFLD Nomenclature consensus group. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. J Hepatol. 2023;79:1542-56.

13. Henney AE, Riley DR, Hydes TJ, et al. Metabolic syndrome traits differentially and cumulatively influence micro- and macrovascular disease risk in patients with MASLD. Liver Int. 2024;44:3031-49.

14. Shang Y, Grip ET, Modica A, et al. Metabolic syndrome traits increase the risk of major adverse liver outcomes in type 2 diabetes. Diabetes Care. 2024;47:978-85.

15. Riley DR, Hydes T, Hernadez G, Zhao SS, Alam U, Cuthbertson DJ. The synergistic impact of type 2 diabetes and MASLD on cardiovascular, liver, diabetes-related and cancer outcomes. Liver Int. 2024;44:2538-50.

16. Chan KE, Ong EYH, Chung CH, et al. Longitudinal outcomes associated with metabolic dysfunction-associated steatotic liver disease: a meta-analysis of 129 studies. Clin Gastroenterol Hepatol. 2024;22:488-98.e14.

17. Jamalinia M, Zare F, Noorizadeh K, Bagheri Lankarani K. Systematic review with meta-analysis: steatosis severity and subclinical atherosclerosis in metabolic dysfunction-associated steatotic liver disease. Aliment Pharmacol Ther. 2024;59:445-58.

18. Han E, Lee BW, Kang ES, et al. Mortality in metabolic dysfunction-associated steatotic liver disease: a nationwide population-based cohort study. Metabolism. 2024;152:155789.

19. Wongtrakul W, Charatcharoenwitthaya N, Charatcharoenwitthaya P. Metabolic dysfunction-associated steatotic liver disease and the risk of mortality in individuals with type 2 diabetes: a systematic review and meta-analysis. Eur J Gastroenterol Hepatol. 2024;36:351-8.

20. Dobbie LJ, Kassab M, Davison AS, Grace P, Cuthbertson DJ, Hydes TJ. Low screening rates despite a high prevalence of significant liver fibrosis in people with diabetes from primary and secondary care. J Clin Med. 2021;10:5755.

21. Buchanan RM, Reinson T, Bilson J, et al. Screening to identify people with type 2 diabetes at risk of liver cancer in primary care: a randomised controlled trial protocol. BMJ Open. 2025;15:e088043.

22. Lindfors A, Strandberg R, Hagström H. Screening for advanced liver fibrosis due to metabolic dysfunction-associated steatotic liver disease alongside retina scanning in people with type 2 diabetes: a cross-sectional study. Lancet Gastroenterol Hepatol. 2025;10:125-37.

23. Mansour D, Grapes A, Herscovitz M, et al. Embedding assessment of liver fibrosis into routine diabetic review in primary care. JHEP Rep. 2021;3:100293.

24. Moolla A, Motohashi K, Marjot T, et al. A multidisciplinary approach to the management of NAFLD is associated with improvement in markers of liver and cardio-metabolic health. Frontline Gastroenterol. 2019;10:337-46.

25. Fowell AJ, Fancey K, Gamble K, et al. Evaluation of a primary to secondary care referral pathway and novel nurse-led one-stop clinic for patients with suspected non-alcoholic fatty liver disease. Frontline Gastroenterol. 2021;12:102-7.

26. Clayton M, Fabrellas N, Luo J, et al. From NAFLD to MAFLD: nurse and allied health perspective. Liver Int. 2021;41:683-91.

27. Stine JG, Bradley D, McCall-Hosenfeld J, et al. Multidisciplinary clinic model enhances liver and metabolic health outcomes in adults with MASH. Hepatol Commun. 2025;9:e0649.

28. Allen MJ, Tulleners R, Brain D, et al. Implementation of a nurse-delivered, community-based liver screening and assessment program for people with metabolic dysfunction-associated steatotic liver disease (LOCATE-NAFLD trial). BMC Health Serv Res. 2025;25:421.

29. Qadri S, Yki-Järvinen H. Surveillance of the liver in type 2 diabetes: important but unfeasible? Diabetologia. 2024;67:961-73.

30. Merriel SW, Lee L, Neal R. Community diagnostic centres: bringing diagnostics closer to home. Br J Gen Pract. 2021;71:534-5.

31. Kjaergaard M, Lindvig KP, Thorhauge KH, et al. Screening for fibrosis promotes lifestyle changes: a prospective cohort study in 4796 individuals. Clin Gastroenterol Hepatol. 2024;22:1037-47.e9.

32. Subhani M, Enki DG, Knight H, et al. Does knowledge of liver fibrosis affect high-risk drinking behaviour (KLIFAD): an open-label pragmatic feasibility randomised controlled trial. EClinicalMedicine. 2023;61:102069.

33. Guzder RN, Gatling W, Mullee MA, Byrne CD. Impact of metabolic syndrome criteria on cardiovascular disease risk in people with newly diagnosed type 2 diabetes. Diabetologia. 2006;49:49-55.

34. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA. 2001;285:2486-97.

35. Kanwal F, Kramer JR, Mapakshi S, et al. Risk of hepatocellular cancer in patients with non-alcoholic fatty liver disease. Gastroenterology. 2018;155:1828-37.e2.

36. Alberti K, Zimmet P; WHO Consultation. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus. Provisional report of a WHO consultation. Diabet Med. 1998;15:539-53.

37. Bilson J, Hydes TJ, McDonnell D, et al. Impact of metabolic syndrome traits on kidney disease risk in individuals with MASLD: a UK biobank study. Liver Int. 2025;45:e16159.

38. Alberti KG, Eckel RH, Grundy SM, et al; International Diabetes Federation Task Force on Epidemiology and Prevention; Hational Heart, Lung, and Blood Institute, American Heart Association, World Heart Federation; International Atherosclerosis Society, International Association for the Study of Obesity. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009;120:1640-5.